The US Food and Drug Administration (FDA) has made a surprising U-turn, deciding to review Moderna's mRNA flu vaccine after initially rejecting it. This decision comes as a relief to many, especially after the initial rejection raised concerns about the technology's future. But here's where it gets controversial... The FDA's initial refusal was based on the argument that the control arm of the trial didn't reflect the 'best-available standard of care in the United States at the time of the study'. However, Moderna has since met with the FDA and proposed a revised regulatory approach, seeking full approval for adults aged 50 to 64 and accelerated approval for those aged 65 and above. If approved, the vaccine could be available for people aged 50 and over for the upcoming 2026-2027 flu season. This development raises an important question: Is the FDA's initial refusal a one-time blunder or a sign of a deeper issue with the regulatory process? And this is the part most people miss... The FDA's decision to review the vaccine after all could set a precedent for other mRNA vaccines in the future. So, what do you think? Do you think the FDA's initial refusal was a one-time blunder or a sign of a deeper issue? Share your thoughts in the comments below!
